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emerging Therapies for Stage iii 
Non-Small Cell Lung Cancer: 
Stereotactic Body Radiation  
Therapy and immunotherapy
Sameera S. Kumar1, Kristin A. Higgins2 and Ronald C. McGarry1*
1 Department of Radiation Medicine, University of Kentucky, Lexington, KY, United States, 2 Department of Radiation 
Oncology, Winship Cancer Institute of Emory University, The Emory Clinic, Atlanta, GA, United States
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) 
includes radiation, chemotherapy, and surgery in certain individualized cases. In unre-
sectable NSCLC, chemoradiation has been the standard of care for the past three 
decades. Local and distant failure remains high in this group of patients, so dose esca-
lation has been studied in both single institution and national clinical trials. Though initial 
studies showed a benefit to dose escalation, phase III studies examining dose escalation 
using standard fractionation or hyperfractionation have failed to show a benefit. Over the 
last 17 years, stereotactic body radiation therapy (SBRT) has shown a high degree of 
safety and local control for stage I lung cancers and other localized malignancies. More 
recently, phase I/II studies using SBRT for dose escalation after conventional chemo-
radiation in locally advanced NSCLC have been promising with good apparent safety. 
Immunotherapy also offers opportunities to address distant disease and preclinical 
data suggest immunotherapy in tandem with SBRT may be a rational way to induce an 
“abscopal effect” although there are little clinical data as yet. By building on the proven 
concept of conventional chemoradiation for patients with locally advanced NSCLC with 
a subsequent radiation dose intensification to residual disease with SBRT concurrent 
with immunotherapy, we hope address the issues of metastatic and local failures. This 
“quadmodality” approach is still in its infancy but appears to be a safe and rational 
approach to the improving the outcome of NSCLC therapy.
Keywords: stereotactic body radiation therapy, immunotherapy, radiation therapy, non-small cell lung cancer, 
stage iii
CHeMORADiATiON iN STAGe iii NON-SMALL  
CeLL LUNG CANCeR (NSCLC)
One hundred years ago, lung cancer was a rare malignancy (1). Lung cancer today is the leading 
cause of cancer death in the United States, with over 158,000 estimated deaths in 2016 (2). Forty 
percent of these patients present with locally advanced disease (3). Approximately 80–90% of newly 
diagnosed lung cancers are classified as NSCLC, primarily consisting of adenocarcinoma, squamous 
cell carcinoma, or large cell carcinoma histologies. Historically, surgery has been the gold standard 
for newly diagnosed NSCLC with early-stage resectable disease, resulting in 5-year overall survival 
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rates (OS) of 50–70%. However, for patients with more locally 
advanced NSCLC, 5-year OS after treatment with definitive 
radiation therapy and concurrent chemotherapy remains mod-
est, at approximately 15–20% (4). Prior to the advent of cytotoxic 
chemotherapy, lung cancer at all stages was treated surgically or 
by radiation alone (5, 6). TNM staging was introduced in 1974 
and it helped shape the way lung cancer was managed. Stage III 
lung cancer, though heterogeneous in its classification, includes 
non-metastatic but locally advanced disease with involvement 
of N1–N3 nodal stations and/or T3 and T4 primaries. Presently, 
stage III lung cancer is managed with a combination of chemo-
therapy, radiation therapy, and sometimes surgery but the two 
major challenges in improving outcomes of the treatment of this 
disease remain local control and metastatic spread.
CHeMORADiOTHeRAPY (CRT)  
DOSe iSSUeS
Multiple studies have examined the issue of the optimal dose of 
radiotherapy in NSCLC but are complicated by the heterogeneity 
of the disease itself in terms of size and location of the primary 
tumor, number and size of involved lymph nodes, and the patient’s 
comorbidities, all of which limit the treatment tolerability and 
risks. Delivery of tumoricidal doses to the primary tumor and 
involved lymph nodes is balanced by treatment-related toxicities, 
namely esophagitis, pneumonitis, and cardiac injury.
An early dose-finding study by the Radiation Therapy 
Oncology Group (RTOG) 7301 study was conducted from 1973 
to 1978 and studied four different doses and schedules: 40  Gy 
split course, 40 Gy continuously, 50 Gy, and 60 Gy. All doses were 
given in 2 Gy fractions. The optimal dose was determined to be 
60 Gy (7).
Further improvements in survival were sought by the incor-
poration of chemotherapy. The Cancer and Leukemia Group B 
8433 study solidified chemotherapy’s importance in the treat-
ment of locally advanced lung cancer. In this phase III study, 
155 patients with stage III NSCLC were randomized to receive 
60  Gy in 30 fractions or induction chemotherapy consisting 
of two cycles of cisplatin and vinblastine followed by 60  Gy 
in 30 fractions. Both median OS (13.8 versus 9.7 months) and 
3-year OS were improved in the CRT arm (23 versus 11%) (8). 
Likewise, a European Organisation for Research and Treatment 
of Cancer study showed a benefit to concurrent CRT by rand-
omizing patients to split-course radiotherapy alone to a dose of 
55  Gy, split-course radiotherapy plus low-dose daily cisplatin, 
and split-course radiotherapy plus higher dose weekly cisplatin. 
The most salient differences were seen between concurrent daily 
CRT and radiation alone with the 3-year OS for CRT being 16 
versus 2% for radiotherapy alone. This difference was thought 
to be due to an improvement in local control, as the 2-year 
local control in the daily CRT arm was 31 versus 19% in the 
radiotherapy alone arm (9).
Only one phase III trial has compared the traditional standard 
of 60 Gy to a modestly escalated dose regimen of 74 Gy. Based 
on the results of RTOG 0117 suggesting that 74 Gy represented a 
maximum tolerated dose of CRT for most patients, RTOG 0617 
compared 60 versus 74 Gy both combined with weekly carboplatin 
and paclitaxel. In this four-arm study, a second randomization of 
cetuximab versus observation was also studied. Unfortunately an 
interim analysis showed that the 74 Gy arm had increased risk of 
death, with a median survival of 20 months for patients receiving 
74  Gy versus 29  months for patients receiving 60  Gy, leading 
to early termination of the study (10). There was no benefit to 
local control. Of note, the 60  Gy arm had the highest median 
survival demonstrated within a phase III trial for this patient 
population. On multivariate analysis, increased dose to the heart, 
represented as heart V5 and V30 (the percent volume receiving 
≥5 and ≥30 Gy, respectively), maximum esophagitis grade, plan-
ning target volume, and radiation dose (74 Gy) were all shown 
to negatively impact overall survival. There were no statistically 
significant differences in ≥grade 3 toxic effects between the 
groups; however, heart-specific toxicities were not assessed in this 
trial. Ultimately this underlines the difficulty of dose escalation 
with conventional radiation therapy fractionation techniques in 
the general population of patients with stage III NSCLC, open-
ing the door for new strategies to improve outcomes for locally 
advanced disease. Often the argument is put forth that surgery is 
the ultimate form of local control and indeed 5-year local control 
rates for locally advanced NSCLC after CRT have been reported 
as low as 15%, but at least some of this is possibly biased by the 
selection of more resectable patients receiving surgery (11). 
Improving local control of the primary lesion in NSCLC does 
influence overall survival, as demonstrated by a meta-analysis of 
concurrent CRT versus sequential chemotherapy and radiation 
(12). Thus, if radiation techniques could be optimized and local 
control improved, one could expect to see improvement in long-
term patient survival.
iNDiviDUALiZeD CRT
Since most dose-escalation studies have produced problematic 
results in relatively unselected patients, can escalated radiation 
doses safely be delivered to patients by adaptive radiotherapy 
either during or after conventional radiotherapy? Additionally, 
in an era of intense research into molecular markers and innova-
tive systemic therapies, how can combination strategies best be 
utilized to improve both local control and risk of metastasis?
Radiation Therapy Oncology Group 9311 was an early 
multi-center dose-escalation trial of 179 patients which used 
radiotherapy alone (13). The treatment was individualized based 
on the volume of lung receiving 20 Gy or more (V20). Those with 
a V20 less than 25% were dose-escalated to 90.3 Gy. Those with 
a V20 of 25–36% were dose-escalated to 83.8 Gy. Both schemes 
were performed at 2.15 Gy per fraction. Two treatment-related 
deaths occurred in the 90.3 arm and this dose was labeled as 
too toxic. Elective nodal coverage was not allowed, but still the 
isolated nodal failure rate was less than 10%. For the group with a 
V20 less than 25%, 83.8 Gy was found to be safe and for the group 
with a V20 of 25–36% 77.4 Gy was found to be safe.
More recently Kong et al. reported results of a phase II study 
of mid-treatment positron emission tomography-computed 
tomography (PET/CT) adapted radiotherapy with concur-
rent chemotherapy (14). Briefly, in this study, 43 patients with 
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unresectable stage II–III NSCLC received radiotherapy with 
doses individualized for an allowable mean lung boost dose of 
up to 20 Gy which would produce a risk of pneumonitis up to 
17.5%. Radiation was delivered in 30 fractions with all patients 
receiving 2.1–2.85 Gy/fraction for the initial dose up to approxi-
mately 50 Gy EQD2 with the adaptive phase of the treatment of 
2.85–5.0 Gy/fraction for a total radiation dose of up to 86 Gy in 
an attempt to deliver >100 Gy BED10. Weekly carboplatin and 
paclitaxel were given concurrently. After a median follow-up of 
47  months, the 2-year infield and overall local regional tumor 
controls were 82 and 62%, respectively; and median OS was 
25%. Overall these results are consistent with most other stage 
III studies. This promising strategy of mid-treatment PET with 
dose escalation is currently being evaluated in the RTOG 1106 
randomized trial, which recently completed accrual. Though 
local control has improved with these trials, metastatic disease 
still remains an important site of failure.
Stereotactic body radiation therapy (SBRT) has changed the 
standard of care for early-stage lung cancer, and data are emerg-
ing showing applicability to the stage III NSCLC population. The 
evidence for a role of SBRT in the stage III lung cancer population 
is summarized within this review.
BiOLOGiCALLY eFFeCTive DOSe (BeD) 
AND SBRT
The success of SBRT treatments in early-stage NSCLC likely 
reflects the radiobiologic properties of high radiation doses. 
Higher radiation doses result in exponential increases in cell kill, 
and may also have an ablative effect on tumor vascularity and 
stroma (15, 16). A method of dose modeling based on the linear 
quadratic model of cell killing, referred to as the BED, takes into 
account the radiation dose per fraction and the inherent radiation 
response of a particular tissue (17). As derived from linear quad-
ratic curves, mathematically two different dose and fractionation 
schemes can be compared theoretically for tumor control prob-
ability. An important assumption of this model is referred to as the 
α/β ratio, simplistically thought of as the ratio of cell killing based 
on single hit and multi-hit kinetics that leads to local control of 
a cancer mass (primarily from cell culture experiments, animal 
data and clinical observation). Nevertheless, tumor control prob-
abilities are more complicated than a simple mathematical state-
ment since tissues are complicated structures with underlying 
vasculature, stroma, and tumor cells, all of which interact (18). 
Many of the α/β assumptions are, therefore, also based on long 
clinical observation of tumor control and normal tissue toxici-
ties. The BED equation can be expressed as BED = nd(1 + d/α/β) 
where n =  the number of fractions, d =  the dose/fraction, and 
α/β =  alpha-beta ratio. Often early-reacting tissues/tumor cells 
are considered to have an α/β of approximately 10 whereas late 
reacting tissues are assigned an α/β of approximately 3. Based 
on these assumptions, Martel et al. constructed a mathematical 
model which predicted that in NSCLC a dose 84  Gy must be 
achieved for a local progression-free survival (PFS) of greater 
than 30 months (19). A retrospective study found that the doses 
of at least 70 Gy at 1.8–2 Gy per fraction provided better local 
control and survival for tumors less than 100 cc (20). Using 2 Gy 
fractions, a dose of 70 Gy has a BED of 84 Gy.
Based on the success of Gamma Knife treatment of brain 
lesions, extremely hypofractionated extracranial stereotactic 
radiotherapy programs began in the 1990s and are commonly 
known as SBRT or stereotactic ablative radiation therapy. SBRT 
treatments, because of the high dose per fraction, are able to 
achieve a much higher BED to localized volumes than conven-
tional radiation delivered at 2 Gy/fraction. Multiple studies have 
demonstrated that a higher BED is correlated with improved local 
control and survival (21–24). Onishi et  al. have shown that in 
early-stage lung cancer, superior local control and survival are 
achieved with treatment regimens that reach a BED of 100 Gy 
or greater (21). Specifically in lung cancer, SBRT delivers a high 
dose per fraction, with robust immobilization that minimizes 
intra-fraction motion and tumor-related internal motion, allow-
ing for overall reduction in size of treatment volumes and overall 
treatment time.
In the seminal clinical reports by Blomgren and Lax, the 
philosophy and treatment parameters for the hypofractionated 
highly conformal treatment of localized disease that we use today 
were elucidated (25). In an ad hoc manner, they treated a number 
of different sites of localized disease most notably early-stage lung 
cancers settling on a dose of 60 Gy in three fractions of 20 Gy each 
with excellent local control and minimal toxicity. Their studies 
defined the parameters required for safe and precise delivery that 
we utilize in SBRT delivery today. Presciently, they speculated that 
“this new technique may also be used for delivering boost doses 
with a high precision after conventional radiation therapy” (26).
SBRT CLiNiCAL TRiALS iN  
eARLY-STAGe LUNG CANCeR
In an effort to better define SBRT doses for localized disease, 
Timmerman et  al. performed a phase I-II dose-escalation 
study for SBRT to the primary tumor in patients with stage I 
NSCLC using the concept derived from Swedish studies (27). 
Inhomogeneity corrections to correct for lung density were not 
performed. Separate cohorts of patients were followed with the 
dose-escalation ending at 60 Gy in 20 Gy fractions with no dose-
limiting toxicity. Termination of the dose escalation for these 
smaller tumors was based on modeling of cell kill. For larger 
tumors (up to 7.0  cm) a dose-limiting toxicity (pneumonitis) 
was reached at 72  Gy in 24  Gy fractions. This experience laid 
the groundwork for further national clinical trials evaluating 
SBRT as a therapy for medically inoperable early-stage NSCLC, 
and ultimately changed the standard of care for these patients. 
Currently, SBRT is defined as 1–5 treatments of high-dose radia-
tion delivered to tumors, typically measuring up to 7 cm, with 
registration of the patient’s anatomy to a 3-D coordinate system 
either physical or within the planning system. SBRT is considered 
an ablative treatment intended to disrupt cellular clonogenicity, 
and lead to cell death. Robust immobilization, control of internal 
organ and tumor motion, sharp dose gradients, and high dose 
per fraction (≥600  cGy) for five or fewer fractions have been 
considered to define SBRT.
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The first North American prospective cooperative group clini-
cal trial evaluating SBRT, RTOG 0236 began accrual in 2004 and 
only allowed “peripherally located” tumors as defined by being 
outside 2  cm of the proximal bronchial tree or mediastinum 
(commonly referred to as the “no fly” zone). This study accrued 
59 patients, treated with 18 Gy × 3 (total 54 Gy with heterogeneity 
corrections) to the primary tumor, and demonstrated 3-year local 
control (involved tumor and primary lobe) of 91% for patients 
with T1-2, N0 medically inoperable lung cancer (28). Three-year 
local–regional control was 87%, and distant failure rate was 22%. 
Overall survival was 56%. Results from longer follow-up have 
shown higher rates of local failure, primarily due to intralobar 
recurrences, with 5-year local recurrence rates of 20% (29). 
Importantly, these clinical outcomes are far better than histori-
cal studies treating medically inoperable early-stage lung cancer 
with conventionally fractionated radiation (2 Gy/fraction), with 
dismal local control of the primary tumor of 50% or less (30). 
Grade 3 and higher adverse events occurred in approximately 
15% of patients enrolled in RTOG 0236.
For centrally located tumors, RTOG 0813 was a phase I-II 
study for T1-2, N0 medically inoperable lung cancer 5 cm or less 
in size, centrally located within or touching the 2 cm bronchial 
tree “no fly” zone. The primary endpoint was to establish the opti-
mal SBRT dose for centrally located tumors. With dose cohorts of 
10 Gy × 5, 10.5 Gy × 5, 11 Gy × 5, 11.5 Gy × 5, and 12 Gy × 5, it 
was found that the highest dose cohort had a 7% probability of a 
dose-limiting toxicity (31). RTOG 0915 was a randomized phase 
II study designed to test 34 Gy × 1 versus 12 Gy × 4 for non-
centrally located tumors, with a primary endpoint of determina-
tion of the regimen with the lowest rates of protocol specified 
adverse events at 1 year. One year adverse events were 10% for 
the 34 Gy arm, and 13% for the 48 Gy arm (32).
It thus appears that there are multiple hypofractionated 
schemes that are acceptable using SBRT techniques to achieve 
high degrees of local control but they all have one thing in com-
mon: BED > 100.
SBRT TOXiCiTY
Though grade 3–5 toxicities with SBRT are overall low, Timmerman 
et al. retrospectively found in the initial single institution phase II 
study that 20–22 Gy × 3 was overly toxic for tumor in a central 
location, defined as within 2 cm from the proximal bronchial tree. 
In this phase II study, 2-year freedom from severe toxicity was 
83% in patients with peripheral tumors and 54% for patients with 
central tumors (33). A separate single institution study recently 
showed a 3.7% fatal toxicity rate for SBRT with central tumors, 
with tumors abutting the proximal bronchial tree having signifi-
cantly more grade 3+ adverse events (31 versus 7%) (34).
This suggests that tumor location with regards to the potential 
for late toxicity attributable to SBRT may be important as described 
above, but the RTOG 0813 SBRT dose-escalation study shows 
that central tumors may be safely treated to significant SBRT 
doses (31). As data and experience accumulates, dose-limiting 
organs within the hilum and mediastinum are becoming better 
defined and with care, SBRT can be utilized to treat “central” 
tumors safely.
Nonetheless, a large body of literature is accumulating con-
firming that SBRT treatment is well tolerated and safe in patients 
who are medically inoperable with early-stage lung cancer and 
produces excellent results. The question of applying SBRT to a 
stage III population with centrally located mediastinal lymph 
nodes as well as primary tumors remains pertinent. The studies 
summarized below describe the experience of SBRT in the locally 
advanced, stage III patient population.
DOSe-eSCALATeD HYPOFRACTiONATeD 
RADiATiON (SBRT) iN STAGe iii NSCLC
Investigators at the University of Kentucky completed a prospec-
tive study evaluating the feasibility of conventional CRT followed 
by a SBRT boost to the primary tumor as a method to dose escalate 
in patients with residual disease following CRT (35). In this study, 
patients with stage IIIA and IIIB NSCLC received CRT (median 
dose of 59.4 Gy) followed by a whole body fluorodeoxyglucose-
positron emission tomography (FDG-PET) scan 1 month after 
treatment. Eighty-nine percent of patients received concurrent, 
platinum-based chemotherapy during CRT. Patients were 
eligible for SBRT if they had evidence of residual disease at the 
primary tumor location that was ≤5 cm in greatest dimension. 
Patients with progressive metastatic disease, contralateral lung 
disease or residual disease in the hilum or mediastinum were 
not eligible (defined as SUV ≥ 2). SBRT doses were 6.5 × 3 for 
centrally located primary tumors, and 10 Gy × 2 for non-central 
tumors. With these dose schemas, the cumulative BED10 to the 
primary tumor was 110 Gy for non-central tumors and 102 Gy for 
centrally located tumors. Sixty-two patients were screened, and 
37 patients were ultimately eligible and enrolled. Approximately 
31% of patients screened had new metastatic disease and an 
additional 31% had persistent nodal disease on post-treatment 
FDG-PET. The primary endpoint of this study was to assess 
the proportion of patients who developed ≥grade 3 radiation 
pneumonitis, according to the RTOG acute and late radiation 
morbidity scoring criteria. Overall, 11.4% of patients experienced 
radiation pneumonitis consistent with rates found in most studies 
of conventional CRT suggesting no increase risk with the SBRT 
boost. Two patients developed fatal pulmonary hemorrhage felt 
to be possibly related to treatment but careful analysis showed 
that these cases were more likely to have been related to squamous 
cell cavitary recurrences involving the hilum (36). Statistically 
there were no differences dosimetrically between patients who 
developed a fatal hemorrhage from those who did not. Local 
recurrence remained the most significant predictor. The central 
structures including the bronchial walls, pulmonary arteries, and 
aorta were contoured and the individual doses delivered to these 
structures were compared as well as the location of the PTV to the 
hilum. This small series of patients suggested that it is prudent to 
restrict the maximum radiation dose to the pulmonary artery to 
less than 185 Gy cumulative BED3, and to less than 120 Gy BED3 
for the 5 cc volume; as well as limiting the maximum dose to the 
bronchial wall to less than 175 Gy BED3. The equivalent dose on 
a per fraction basis would be equivalent to limiting each of these 
structures to less than 700 cGy per fraction times 3, or 900 cGy 
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per fraction times 2 for the boost, assuming that the patient 
has previously received between 60 and 66  Gy using standard 
fractionation. The most recently reported long-term follow-up of 
this study shows a crude local control rate of 78%. Median overall 
survival was 25 months. There were no significant late toxicities 
seen within the study population (37).
Second, a recent phase I study by Higgins et al. (in press) evalu-
ated the optimal SBRT dose after 44 Gy CRT. Inclusion criteria 
included stage IIIA or IIIB NSCLC, with a primary tumor of 8 cm 
or less and no N1 or N2 nodal station >5 cm in maximum dimen-
sion. This multi-institution phase I study enrolled 15 patients, 
and dose-escalated a SBRT boost according to the following dose 
cohorts: 9 Gy × 2, 10 Gy × 2, 6 Gy × 5, 7 Gy × 5. Patients received 
44 Gy with weekly carboplatin and paclitaxel, and then underwent 
a second computed tomography (CT) simulation after 40 Gy was 
delivered. The SBRT boost was then planned to encompass all 
residual primary and nodal disease as seen on the planning CT 
simulation. This volume was then dose-escalated according to the 
dose assignment of the patient. The maximum tolerated dose was 
determined to be 6 Gy × 5. There was one treatment-related grade 
5 toxicity at this dose level, and 10 Gy × 2 is felt to be the most 
optimal SBRT boost dose, as no grade 3 or higher toxicities were 
seen in patients treated within the dose cohort. For all patients, 
actuarial local regional control at 3  years was 59%, and 3-year 
overall survival was 39% (38).
In an additional phase I study by Hepel et al., 12 patients with 
stage III NSCLC who had a primary tumor volume <120  cc 
(approximately 6.0  cm) and nodal disease volumes <60  cc 
received CRT to a dose of 50.4 Gy in 28 fractions (39). The study 
used a dose-escalation design to identify the maximum tolerated 
dose. SBRT dose was escalated from 16 Gy in two fractions to 
28  Gy in two fractions in 2  Gy/fraction increments, resulting 
in four potential dose cohorts. The endpoint was dose-limiting 
toxicity occurring within 4 weeks of SBRT. A standard phase I 
cohort design was used. SBRT cohort doses started at 800 cGy × 2 
fractions and escalated by 200  cGy/fraction to a final dose of 
1,400 cGy × 2 for a total SBRT boost of 28 Gy. No early grade 3–5 
toxicities were noted and at a median follow-up of 16 months, 
1  year local–regional control was 78% with 100% at ≥24  Gy. 
Overall survival at one year was 67%. One late fatal pulmonary 
hemorrhage was noted and it was determined that the patient’s 
4  cc proximal bronchial-vascular tree dose was substantially 
higher than all patients reported at 30.2 Gy for the SBRT boost 
and 73.5 Gy for the total treatment. A total BED computation was 
not available to assess all patient doses.
It is clear from these studies and RTOG 0813, contouring of at 
risk structures and applied dose constraints (see above estimates) 
particularly for the pulmonary vasculature need to be respected 
in the treatment plan.
iMMUNOTHeRAPY iN NSCLC
The use of immunotherapy in NSCLC is rapidly burgeoning. 
Early vaccine trials and trials with interferon therapy for those 
who were suffering from NSCLC have been largely negative 
and led to the hypothesis that NSCLC was believed to be largely 
non-immunogenic. Clearly, the immune response must be 
tightly controlled to prevent rampant autoimmunity. Multiple 
mechanisms to regulate immune responses have been shown 
to exist including innate tolerance to self-antigens, a network of 
both B and T suppressor cells and more recently elucidation of 
molecular regulatory mechanisms including checkpoint inhibi-
tors. Immune checkpoint inhibitors have shown some promise in 
modulating the tumor microenvironment so that evasion of the 
immune system is more difficult.
Surveillance and destruction of tumor cells is postulated to 
be effected by the immune system and the vanguard of early 
tumor control may be the natural killer cell although its full 
role is yet to be elucidated. Once a tumor is established, control 
may be mediated by activated T-lymphocytes including CD4+ 
and CD8+ cells. The CTLA-4 and programmed death ligand 1 
(PD-1) pathways are two T-cell inhibitory pathways that may 
modulate immune responses to lung antigens in the presence of 
an increasing burden of malignant cells possibly in an effort to 
prevent damage to host normal tissues. Inadvertently this may 
result in suppression of the immune system favoring tumor cell 
survival and growth. A CTLA-4 monoclonal antibody which is 
currently in use is ipilimumab, currently indicated in the treat-
ment of melanoma. The PD-1 receptor ligands include PD-L1 and 
PD-L2. Nivolumab and pembrolizumab are two PD-1 inhibitors 
which have been FDA approved for clinical use in lung cancer.
Several seminal trials suggested the utility of blocking the 
PD inhibitory pathway by monoclonal antibodies to harness the 
immune system in control of NSCLC. The Checkmate 057 phase 
III clinical trial randomized 582 patients with non-squamous 
metastatic NSCLC who had progressed during or after platinum-
based chemotherapy to salvage docetaxel chemotherapy or 
nivolumab. Median OS was longer in the nivolumab group 
(12.2 versus 9.4 months). Patients with even <10%, but greater 
than 1% PD-L1 expression showed a benefit with nivolumab 
over docetaxel (40). A second study, Checkmate 017, studied 272 
patients with metastatic squamous cell NSCLC who progressed 
through platinum-based first-line chemotherapy. Those who 
received nivolumab had a median OS of 9.2 months versus those 
who received docetaxel, with a median OS of only 6.0 months 
(41). The use of nivolumab as a first-line agent was explored in 
the phase III Checkmate 026 trial in which 541 patients with 
previously untreated metastatic NSCLC with at least 1% PD-L1 
expression were randomized to nivolumab or standard-of-care 
platinum doublet chemotherapy. Both PFS and OS were not 
significantly different between the two arms (42).
The KEYNOTE-010 trial enrolled over 1,000 patients with 
previously treated advanced NSCLC with at least 1% PD-L1 
expression. They were randomized to two different doses of 
pembrolizumab or docetaxel. Median OS was 10.4  months 
with 2  mg/kg of pembrolizumab, 12.7  months with 10  mg/kg 
of pembrolizumab, and 8.5  months with docetaxel, which was 
statistically significant. An even greater survival benefit was 
seen in those with >50% tumor PD-L1 expression: 14.9 months 
with 2  mg/kg of pembrolizumab, 17.3  months with 10  mg/kg 
of pembrolizumab, and 8.2  months with docetaxel, which was 
also statistically significant (43). As a first-line therapy, the phase 
III KEYNOTE 024 trial explored the use of pembrolizumab 
in advanced NSCLC with at least 50% PD-L1 staining versus 
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cytotoxic chemotherapy, which was up to the discretion of the 
treating physician. Only 30% of the patients had the required 50% 
or greater PD-L1 staining tumors. In those patients, pembroli-
zumab was seen to significantly increase the 6-month OS (80.2 
versus 72.4%) (44).
PD-L1 reactive monoclonal antibodies are currently being 
explored in NSCLC. Atezolizumab is one such IgG1 agonist to 
PD-L1. In the OAK trial, 1,225 patients with advanced NSCLC 
were randomized to salvage chemotherapy with docetaxel or 
atezolizumab. Greater OS was seen with atezolizumab regardless 
of PD-L1 expression (13.8 versus 9.6 months) (45).
To date, there are only limited data from phase III trials 
regarding immunotherapy for stage III NSCLC. The phase III 
START trial enrolled 1,514 patients with stage III NSCLC who 
had received CRT and had not progressed within 1–3 months. 
Patients were randomized to either placebo or tecemotide, an anti-
MUC-1 immunotherapy designed to stimulate a T-cell response 
against the MUC-1 protein. There was no OS difference between 
the placebo group and the tecemotide group, except in a subgroup 
receiving concurrent CRT. In this case, the tecemotide group did 
have an improved OS (46), suggesting a possible synergistic inter-
action between the radiation and the drug. Belagenpumatucel-L 
is a tumor vaccine of four allogeneic NSCLC cell lines. In a 
phase III trial, 270 stage III or IV patients who were treated with 
platinum-based chemotherapy and who had not progressed were 
randomized to receive placebo or belagenpumatucel-L. There 
were no differences in OS or PFS between the two arms (47). A 
killed Mycobacterium vaccae named SRL172 was the subject of a 
phase III clinical trial published in 2004. A total of 419 patients 
were treated with 6 cycles of mitomycin, vinblastine and cispl-
atin or carboplatin with or without monthly administration of 
SRL172. There were no differences in overall survival, but patients 
in the SRL172 arm reported better quality of life (48). A meta-
analysis of 20 trials by Zhou et al. found an OS benefit to immune 
checkpoint inhibitors and therapeutic vaccine (49).
RATiONALe FOR THe USe OF 
iMMUNOTHeRAPY wiTH RADiOTHeRAPY
Immunogenic cell death is a postulated mechanism of radiation 
injury. Classically it is thought that the immune system must 
recognize either foreign (e.g., viruses) or mutated antigens on 
tumor cells to initiate an immunostimulatory response. Thus 
far, no simple antigen has been identified since in many ways, 
cancer cells are “self.” Roszik et al. found a significant relation-
ship between the predicted tumor mutation load and clinical 
benefit from ipilimumab, T-cell therapy, and pembrolizumab 
suggesting mutated proteins or DNA-protein complexes may be 
immunostimulatory (50). Unlike conventional apoptosis, when 
due to an immunogenic cell death apoptosis causes a release of 
molecules which may lead to an inflammatory or augmented 
immune response (51, 52). Damaged cells produce damage-asso-
ciated molecular patterns which lead to uptake and subsequent 
presentation of tumor antigen by dendritic cells. Radiation has 
been shown to release or upregulate immune and tumor-related 
molecules such as major histocompatibility complex, tumor 
markers, adhesion molecules, cytokines, and many others (53). 
Single doses of 15–25  Gy induced strong T-cell responses, but 
these immune responses were dampened by the use of frac-
tionated radiation or chemotherapy (54). Unfortunately, since 
lymphocytes are so radiosensitive, only a low integral dose is 
needed to kill any surrounding tumor lymphocytes. There is some 
evidence that ablative radiation fraction sizes (at least 6 Gy) or 
high linear energy transfer radiation causes increased release of 
immunogenic antigens. Mouse studies have shown evidence of 
the abscopal effect after use of large fractions (55, 56). A paper by 
Lugade et al. looked at 15 Gy in a single fraction versus 15 Gy in 
5 fractions of 3 Gy in in a mouse melanoma model. They found 
that both fraction sizes lead to tumor-infiltrating lymphocytes 
that were capable of lysing tumor cell targets, but that the larger 
fraction size produced better results (57). A strong antitumor 
immunogenic response was observed in mouse models after 
being treated with a carbon ion beam. This resulted in fewer 
contralateral squamous cell tumors, which is thought to be due 
to an immune-mediated abscopal effect (58). Strictly defined, 
the abscopal effect is the resulting shrinkage or disappearance 
of metastatic deposits following treatment of the primary tumor 
mass. Clinically the abscopal effect is rarely seen, with fewer than 
50 documented cases in the literature (59). Barid et al. propose 
that this is because while radiotherapy provides available antigen, 
it does not provide the necessary co-stimulation of T  cells or 
cytokine release (60). Thus, this presents an opportunity for the 
combined use of radiotherapy and immunotherapy.
Both laboratory and clinical evidence exist regarding the 
advantage of combined radiotherapy and immunotherapy. 
In a murine model of metastasis, squamous cell carcinoma cell 
lines were inoculated into the mouse thigh typically requiring 
≥106 tumor cells to ensure tumor growth. Most of these cells 
die and release tumor lysis products which may bias treatment 
results. Mice were treated with a single 6  Gy dose of carbon 
ions and 36  h later treated with α-galactosylceramide-pulsed 
dendritic cells. Compared to the untreated control mice, these 
mice developed significantly fewer pulmonary metastases (61). 
Intravenous administration of isolated dendritic cells with either 
carbon beam therapy or photon beam therapy was compared in a 
murine model. Both types of irradiation produced an antimeta-
static effect, but carbon ions did so at a lower BED (62). Sharabi 
et al. examined the effect of SBRT in murine melanoma or breast 
cancer and found that the effect of radiation was enhanced in the 
presence of a PD-1 inhibitor or regulatory T-cell depletion (63). 
Some studies suggest that an immune-mediated abscopal effect 
is increased with fractionated radiotherapy using large fractions 
in addition to a CTLA-4 inhibitor as opposed to single-dose 
radiotherapy (64). Indeed, further mouse studies confirmed that 
fractionation using “medium-sized doses” (7.5 Gy per fraction) 
provided both low numbers of regulatory T-cells and the best 
control of the tumor (65).
Clinical studies also show encouraging results of the use of 
combined radiation and immunotherapy. Abscopal effects in 
humans after SBRT with or without immunotherapy have been 
reported in both renal cell carcinoma and melanoma (66–68). 
The KEYNOTE-001 study predated the KEYNOTE-010 study. 
KEYNOTE-001 was a phase I clinical trial which enrolled 495 
TABLe 1 | Active clinical trials involving the use of both radiotherapy and immunotherapy such as cancer vaccines, CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 
inhibitors in Stage III non-small cell lung cancer (NSCLC).
NCT Number Title Recruitment Study results Phase enrollment
NCT02987998 Neoadjuvant chemoradiation plus pembrolizumab followed by  
consolidation pembrolizumab in NSCLC
Recruiting No results available Phase 1 20
NCT02662634 A safety and feasibility study of AGS-003-LNG for the treatment of stage 3 NSCLC Recruiting No results available Phase 2 20
NCT02434081 NIvolumab consolidation with standard first-line chemotherapy and radiotherapy  
in locally advanced stage IIIA/B non-small cell lung carcinoma
Recruiting No results available Phase 2 43
NCT02318771 Radiation therapy and MK-3475 for patients with recurrent/metastatic head  
and neck cancer, renal cell cancer, melanoma, and lung cancer
Recruiting No results available Phase 1 40
NCT02621398 Pembrolizumab, paclitaxel, carboplatin, and radiation therapy in treating  
patients with stage II-IIIB NSCLC
Recruiting No results available Phase 1 30
NCT02768558 Cisplatin and etoposide plus radiation followed By nivolumab/placebo for  
locally advanced NSCLC
Recruiting No results available Phase 3 660
NCT02125461 A global study to assess the effects of MEDI4736 following concurrent  
chemoradiation in patients with stage III unresectable NSCLC (PACIFIC)
Ongoing, but 
not recruiting
Active, not recruiting Phase 3 713
7
Kumar et al. Emerging Therapies in Lung Cancer
Frontiers in Oncology | www.frontiersin.org September 2017 | Volume 7 | Article 197
patients with advanced NSCLC. They were treated with pem-
brolizumab at doses of 10 mg/kg every 3 weeks or 10 mg/kg every 
2 weeks. The objective response rate was found to be 19.4% and OS 
was 12 months. In patients with at least 50% expression of PD-L1 
median overall survival was not reached. It was deemed to have 
an acceptable side effect profile and the most common side effects 
included fatigue, itching, and decreased appetite (69). An analysis 
of the trial was done and showed that in 97 patients who had 
prior radiation PFS and overall survival were significantly longer, 
especially for those who received extracranial radiotherapy (70). 
In the PACIFIC study, a phase III study for stage III unresectable 
lung cancer, patients in the experimental arm received chemora-
diation followed by durvalumab for 12 months. In a preliminary 
report, Astra Zeneca suggests an improvement in PFS in the 
immunotherapy arm was seen, however, these data have yet to be 
presented (71). Currently, there are several ongoing clinical trials 
investigating the use of immunotherapy with radiotherapy. These 
trials include agents such as cancer vaccines, CTLA-4 inhibitors, 
PD-1 inhibitors, and PD-L1 inhibitors (Table 1). This table was 
generated by searching the ClinicalTrials.gov database with 
search terms such as “radiation,” “chemoradiation,” “thoracic RT,” 
and several variations. The results were then manually filtered for 
the inclusion of Immunotherapy.
SUMMARY
Treatment of locally advanced lung cancer has not made great 
strides since the 1990s when cytotoxic chemotherapy was combined 
with radiation. The two major stumbling blocks to improvements 
in survival of these patients are local control and distant metastasis. 
It is clear that SBRT for stage I NSCLC is one of the most important 
treatment advancements in decades with excellent outcomes of 
high local tumor control and survival with low toxicity.
Cytotoxic chemotherapy remains an important modality in 
more advanced disease but has reached a point where major 
improvements are unlikely and despite systemic therapy, meta-
static disease is a prominent cause of death in locally advanced 
NSCLC patients.
We need more innovative approaches to management of this 
disease. Evidence is accumulating that dose escalation of radio-
therapy improves local control of much of the microscopic and 
gross disease in the chest. Since dose escalation by conventional 
radiation delivery has been compromised by toxicity, the careful 
delivery of hypofractionated radiation therapy (SBRT) to the 
sites of gross disease should improve local control by ablating 
any residual viable cancer cells. The initial studies of SBRT boost 
while small, show this approach is safe and feasible, but the 
impact of this approach on survival in the management of stage 
II-III awaits larger studies.
The sequencing and combination of this “quadmodal-
ity” approach is still being explored. In the Phase I/II studies 
described above, concurrent chemoradiation to a dose of 
44–60 Gy was used which was followed by an SBRT boost. The 
trials showed favorable toxicity profiles using this approach. 
Fractionated chemoradiation promotes immunotolerence 
through the killing of lymphocytes by the chemotherapy and 
radiation therapy, but SBRT has been shown to induce strong 
T-cell responses. Thus ideally the patient would undergo 
concurrent chemoradiation to a dose of 44–60  Gy, have an 
approximately 2-week break to allow for SBRT treatment plan-
ning and recovering from leukopenia, then get an SBRT boost. 
In order to capitalize on the immunostimulatory effects of the 
SBRT, the immunotherapy should be administered soon (within 
1  week) of the SBRT boost. Cranial stereotactic radiosurgery 
with concurrent immunotherapy appears to be well tolerated, 
but data on lung SBRT and concurrent immunotherapy is still 
developing. Theoretically, there could be an increased risk for 
toxicity, especially induced auto-immune effects, due to this 
quadmodality approach. Indeed, the SBRT boost followed by 
immunotherapy may prime the immune system to attack not 
only tumor cells but normal tissue as well.
From a metastatic viewpoint, immunotherapy is an exciting 
option that is still in its infancy. There are adequate early and 
non-clinical data suggesting that hypofractionated radiation and 
immunomodulation may be synergistic. Thus, a more cogent 
approach to trials addressing both local control and metastatic 
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disease may become “quadmodality” and include combining 
chemotherapy, conventionally fractionated radiation therapy, 
immunotherapy and SBRT dose intensification to ablate the 
residual primary tumor mass. Given the continued devastating 
effect of lung cancer on the world, such trials need to be devel-
oped promptly.
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